Post-operative atrial fibrillation (POAF) is a frequent complication after open-heart surgery, and cardioversions (CV) are commonly performed to restore sinus rhythm. However, little data exists on thrombo-embolic risk related to early post-operative CV and on the recurrence of POAF after CV. CAREAVR study sought to assess the rate of strokes, transient ischaemic attacks (TIA), and mortality shortly after POAF-triggered CV in patients who underwent isolated surgical aortic valve replacement (SAVR) with a bioprosthesis. 
Introduction
New-onset post-operative atrial fibrillation (POAF) is a complication after open-heart cardiac surgery that affects 20-50% of patients. 1, 2 Post-operative atrial fibrillation is associated with a variety of adverse consequences, including prolonged hospitalization, increased rates of complications and mortality, and increased costs. 1, 2 Post-operative atrial fibrillation is often considered a temporary, surgery-associated phenomenon and, therefore, rhythm control-using antiarrhythmic agents and/or on-demand electrical cardioversion (CV)-is a frequently used strategy. Early post-operative CV for POAF is performed to achieve better haemodynamic status, to maintain sinus rhythm in the long-term, and to reduce the risk of thrombo-embolic complications. A recent study of cardiac surgery patients showed that, after 60 days of follow-up, post-operative rhythm control therapy combining amiodarone and on-demand CV was non-inferior when compared to rate-control therapy in terms of hospitalization length and recurrence rate of AF. 3 Nevertheless, CV is known to be associated with a temporary increase in stroke risk. Although the risk is less than 1% in patients with adequate anticoagulation in an elective setting or after CV for acute AF, 4-8 the thrombo-embolic risk associated with CV performed for POAF after open-heart surgery remains unknown. Moreover, little is known about the usefulness of the CV strategy in maintaining sinus rhythm after cardiac surgery in real-life practice. The CAREAVR study sought to assess the rate of POAF and thromboembolisms in patients undergoing an isolated surgical aortic valve bioprosthesis (SAVR) operation. In this pre-specified analysis, short-term thrombo-embolic risk and the recurrence of AF were assessed via follow-up among POAF patients who underwent early CV vs. those who did not.
Methods
The CAREAVR is a Finnish multicentre retrospective registry (ClinicalTrials.gov Identifier: NCT02626871) assessing the incidence of AF, thrombo-embolic complications, and bleeding events in patients who have undergone isolated SAVR with a bioprosthesis. This study is part of a broader ongoing protocol in Finland to evaluate the thrombo-embolic and bleeding complications of AF. [7] [8] [9] Patient data were reviewed at four Finnish university hospitals (Helsinki, Turku, Oulu, and Kuopio) that performed open-heart cardiac surgery over the period 2002 (in Helsinki 2006 . Hospital records were reviewed for patients who had undergone open-heart cardiac surgery for isolated SAVR with a biological prosthesis. Patients with concomitant coronary bypass, maze procedure, surgery of the ascending aorta or other valve surgery were excluded. In order to obtain reliable and accurate follow-up data, only patients from the hospitals' catchment areas were included in this study. The patient records were individually reviewed with a standardized structured data-collection protocol for pre-operative and peri-operative data, discharge data, and long-term follow-up events, including POAF, stroke, bleeding, and mortality.
During the period under study, the routine anticoagulation practice in SAVR patients at the study hospitals was enoxaparin 40 mg once a day subcutaneously started on the evening of the day of surgery and continued until vitamin K antagonist (VKA) treatment (started on the first postoperative day) reached the therapeutic level (INR > _ 2.0) irrespective of whether patient had POAF or not. Low dose of enoxaparin was used due to presumed high-bleeding risk shortly after operation.
The endpoints of the study included the first occurrence of any of (i) a composite of stroke, transient ischaemic attack (TIA) or mortality at 30 days; (ii) stroke, TIA, or peripheral arterial embolism; and (iii) mortality, either in-hospital after the index operation or during follow-up after hospital discharge. Strokes were classified using TOAST criteria. For CV-related stroke/TIA event following additional criteria were used: (i) strokes/TIAs diagnosed on the operation date were excluded; and (ii) AF diagnosis was objectively documented prior to stroke/TIA.
The diagnosis of POAF was always confirmed by a 12-lead ECG recording, or telemonitoring indicating AF episode of 10 min or longer. An ischaemic stroke was defined as a permanent focal neurological deficit adjudicated by a neurologist and confirmed via computed tomography or magnetic resonance imaging. Transient ischaemic attack was defined as a transient (<24 h) focal neurological deficit adjudicated by a neurologist. If stroke was clinically diagnosed during index hospitalization by the treating physician and confirmed by computed tomography or magnetic resonance imaging, a separate adjudication by a neurologist was not required. Thus, only ischaemic strokes and TIAs considered definite by the treating neurologist or physician were included in the present study.
An independent, certified third-party data monitor checked the integrity of the data for each study site.
The study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland and the ethics committee of the National Institute for Health and Welfare. Because of the retrospective, registry-based nature of the study, informed consent was not required. The study conforms to the Declaration of Helsinki.
Statistical analyses were conducted with SPSS software (version 21.0, SPSS, Inc., Chicago, IL, USA). Continuous variables were reported as mean ± standard deviation if normally distributed, and as median [interquartile range (IQR)] if they were skewed unless stated otherwise. The data were tested for normal distribution using the KolmogorovSmirnov and Shapiro-Wilk tests. Categorical variables were described with absolute and relative (percentage) frequencies. Comparisons between the two study groups were performed using an unpaired Student's t-test or Mann-Whitney U test for continuous variables, and a Pearson v 2 or Fisher's exact test for categorical variables, as appropriate. Logistic regression analysis was used to identify the independent predictors of strokes at 14 days post-operative follow-up and AF recurrence during long-term follow-up. Two-sided differences were considered significant if the null hypothesis could be rejected at a probability level of 0.05.
Results
A total of 721 patients underwent isolated SAVR with a bioprosthesis at the four hospitals. Of these patients, 87/721 (12.1%) presented with chronic AF, while 96/721 (13.3%) had a history of paroxysmal AF prior to the index operation. During post-operative hospitalization, when patients with prior chronic AF were excluded, a total of 309/634 (48.7%) of patients had at least one POAF episode. The median time to in-hospital POAF was 3 (3) days.
Early post-operative electrical CV was performed in 113/309 (36.6%) of patients with in-hospital POAF. The baseline characteristics of patients who underwent early electrical CV for POAF vs. those who did not are presented in Table 1 . There were no significant baseline differences between the groups, except that patients undergoing early electrical CV more frequently had a history of congestive heart failure and slightly higher estimated risk of stroke according to their CHA2DS2-VASc score, whereas the rate of chronic pulmonary disease was lower. Importantly, a history of prior paroxysmal AF and echocardiography-derived diameter of the left atrium were comparable between the groups. In a multivariate logistic regression model including age, diabetes, hypertension, prior congestive heart failure, coronary artery disease, prior AF, and female gender only prior congestive heart failure remained an independent predictor of POAF-triggered CV.
For the assessment of CV-related thromboembolisms at 2 weeks, stroke/TIA diagnosed on the day of operation, and those diagnosed prior to POAF episode were excluded. At 2 weeks of follow-up in patients with POAF, the incidence of stroke/TIAs was (3.5% vs. 0.5%, P = 0.06) in patients who underwent early CV vs. those who did not, respectively. Table 3 presents detailed patient characteristics of patients with POAF and stroke or TIA at 2 weeks of follow-up. For comparison, the incidence of 2 weeks of stroke was 5/325 (1.5%) and TIA 1 (0.3%) in patients without POAF.
The Kaplan-Meier estimates for a freedom of a composite of stroke, TIA, or mortality at 30 days are presented in Figure 1 . Periand post-operative outcomes are depicted in Table 2 . A composite of stroke, TIA, or mortality at 30 days was more frequent in patients with CV compared to those without CV (9.7% vs. 3.6%, P = 0.04, respectively). In age and sex-adjusted Cox regression model, CV was associated an increased risk of a composite of stroke, TIA, or mortality incidence at 30 days (hazard ratio 2.63, 95% confidence interval 1.00-6.92, P = 0.05). Only one site routinely used CV to treat POAF in patients who were in AF on morning rounds. It appeared that the site had the highest incidence of events. For comparison, incidence of a composite of stroke, TIA, and mortality was 14/300 (4.6%) in patients without post-operative AF. No difference was observed in the length of hospital stay for CV patients compared to those who did not undergo CV. Similarly, the prevalence of patients in AF rhythm was comparable at discharge (32.7% vs. 35.7%, P = 0.18); and at 3 months (25.0% vs. 23.6%, P = 0.40), respectively.
Discussion
The main novel finding of this study was the high incidence of postoperative thrombo-embolic complications and mortality in patients undergoing electrical CV for POAF after SAVR with a bioprosthesis. Patients with an electrical CV had more than two-fold risk for stroke/ TIA/mortality within 30 days from the operation compared to those who did not undergo CV. Atrial fibrillation recurrence rates at discharge and at 3 months follow-up were independent of whether inhospital electrical CV was performed.
These findings have important clinical implications. First, if an electrical CV is performed early after cardiac surgery, an adequate anticoagulation therapy-as recommended for the management of acute and elective CV of AF 10 -is needed. Enoxaparin in prophylactic doses in combination with VKA initiation did not appear to be effective enough to prevent thrombo-embolic complications in our study, despite the fact that the duration of the AF episode was considered short (always <48 h, in most cases <12 h). In fact, more than half of the early strokes/TIAs after electrical CVs occurred when patients were on prophylactic low molecular weight heparin (LMWH) and VKA therapy. In the early post-operative period, patients are in a prothrombotic state related to the major surgery, immobilization, and swelling caused by fluid retention. 1, 2 In addition, the initiation of VKA therapy is also known to suppress proteins C and S levels, and thus, temporarily increase the risk of thrombo-embolic complications. Therefore, it seems clear that more efficacious means of preventing thrombo-embolic complications are needed in this clinical setting. Whether more efficacious prevention can be achieved through more effective anticoagulation such as higher-dose LMWH or non-vitamin K oral anticoagulants, or additional antiplatelet therapy, or surgical exclusion of the left atrial appendage remains to be studied in prospective randomized trials. Second, the decision on whether or not to perform CV in the early post-operative period needs to be thoroughly weighed between the potential benefits of resuming sinus rhythm vs. the risk of adverse thrombo-embolic complications related to the CV procedure. Rhythm control and on-demand CV for in-hospital POAF are often performed because of the presumed higher thrombo-embolic risk of a prolonged AF episode. Based on findings of this study, however, this presumption would not appear to be valid in patients undergoing SAVR operation with a bioprosthesis. A randomized trial of rhythm control achieved through amiodarone combined with on-demand CV vs. rate control for new-onset AF after cardiac surgery showed no benefit over to the rhythm control strategy: days of hospitalization, rates of persistent AF 60 days after the onset, and complication rates were equal between both groups. 3 As compared with our study, the low incidence and absence of differences in cerebrovascular events between the groups in the trial by Gillinov et al. 3 may be explained by differences in the baseline characteristics such as inclusion of patients undergoing isolated coronary artery bypass grafting, lower estimated stroke risk as well as the method of CV and some differences in the analysis of the follow-up data. Another indication In-hospital stay (days) 0.72 Mean (SD) 9.9 (4.6) 11 (6.4) Median (range) 9 (4-39) 9 (4-42)
Delayed ventilation 13 (12) 19 ( for CV in these patients is to achieve better haemodynamic status and earlier discharge. Nevertheless, in our study, hospitalization length was similar in patients who underwent CV compared to those who did not. Third, thrombus formation in the left atrial appendage is usually responsible for the thrombo-embolic complications of AF. The local changes promoting thrombus formation start early after the onset of an AF episode. Platelet activation and increased thrombin generation in the left atrium are measurable as early as 15 min following induction of AF, 11 and profound activation of platelets and coagulation factors has been observed within 12 h of AF. 12 Cardioversion of AF is associated with an increased risk of stroke and systemic embolism. [4] [5] [6] [7] [8] 13 Thus, most embolic events in patients with AF occur after successful CV of AF, and within 1 week from the procedure. In earlier studies, when CV was performed without anticoagulation, the periprocedural risk ranged from 3% to 7%. 4, 6 Later, thanks to effective anticoagulation therapy, the risk of thrombo-embolic complications after elective CV of AF reduced below 0.5%. [14] [15] [16] [17] As a comparison, the long-term thrombo-embolic risk of AF is approximately 0.3% per month, depending on stroke risk factors, and long-term use of oral anticoagulation decreases this risk to 0.1% to 0.2% per month. 18 Moreover, it is possible that cardioembolism originates from another source than left atrial appendage such as from the valve sewing ring before complete endothelialization occurs. Theoretically, electrical CV could dislodge a thrombus attached to the valve sewing ring. Irrespective of the exact source of cardioembolism, however, the 3.5% thrombo-embolic risk within a 2 weeks' period after electrical CV of POAF in the present data exceeds the 'acceptable' risk five-to ten-fold. Although the baseline characteristics of patients who underwent CV vs. those who did not were generally comparable, some differences merit consideration. The CHA 2 DS 2 -VASc score was slightly higher in patients who underwent CV, and these patients more often had a history of congestive heart failure compared to those who did not undergo CV. Nevertheless, this small difference in estimated thrombo-embolic risk is highly unlikely to explain the large difference in the 2 weeks of stroke/TIA rates. Patients who underwent CV had also more frequent and sooner recurrences of AF than patients who did not undergo CV. It is possible that this is due to a more advanced disease burden that cannot be gauged using clinical measures.
We chose to include mortality in the composite endpoint of stroke, TIA and mortality because thrombo-embolic events may result in sudden death. In line, mortality was also included in X-VERT and ENSURE-AF trials assessing the safety of CV with non-vitamin K oral anticoagulants rivaroxaban and edoxaban, respectively. 19, 20 Moreover, the additional 2 weeks' period for CV-associated thromboembolism detection was chosen for two reasons. First, based on our previous findings, >80% thromboembolisms after CV occur within 1 week and >90% within 2 weeks of CV. 7, 13 Second, patients undergoing a SAVR with a bioprosthesis are prone to postoperative stroke, and using the 2 weeks of criteria made it possible to reduce confounding related to competitive causes of thromboembolisms in this patient group, such as thromboembolisms from the valve bioprosthesis or from the aorta. To secure recognition of all major adverse events, such as strokes, TIAs, and major bleeds, only patients living in the hospitals' catchment areas were included in the registry. Methodologically, this study has several strengths. A validated, structured case report form was used at all study sites. As a quality control, a professional third-party monitored the integrity of the data. Moreover, to the authors' knowledge, this is the largest existing study assessing the safety of early post-operative electrical CV after open-heart surgery. Patients with adjunct surgical procedures such as coronary bypass, left atrial appendage occlusion, mace, and pulmonary vein isolation were excluded, and therefore, study population represent relatively homogenous sample of patients undergoing isolated SAVR with a bioprosthesis from four of five Finnish hospitals performing these operations over 10 years enrolment period.
The main limitation of this study is the retrospective nature of data. The decision of rhythm control strategy was at the treating physicians' discretion, and clinical factors not assessed in the case report form may partly account for these decisions. It is also possible that patients who have fluctuating rhythm between sinus rhythm and AF are more likely to be candidates for CV compared to those with only short episodes of AF or those who remain haemodynamically stable in AF. Patients treated with CV may, therefore, have a higher AF burden. Moreover, enoxaparin was used in prophylactic doses instead of full doses because of the presumed high-bleeding risk early after surgery and concomitant VKA initiation. Finally, the number of adverse events was relatively low, but it has been low also in prospective trials such as ENSURE-AF and X-VERT assessing the efficacy of non-vitamin K antagonist vs. warfarin in patients undergoing elective CV of AF.
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Conclusions
In this real-world population of patients without chronic AF undergoing aortic valve replacement with a bioprosthesis, the incidence of inhospital POAF was nearly 50%. One-third of these POAF patients underwent CV, and those who did had more than two-fold risk for thromboembolism or mortality shortly after surgery. The short-term prevalence of AF was not affected by CV.
